by Peter Ciszewski | Dec 6, 2017
Sandesh Seth, Executive Chairman of Actinium Pharmaceuticals discusses the potential market for Iomab-B. Iomab-B via the monoclonal antibody BC8, targets CD45, an antigen widely expressed on leukemia and lymphoma cancer cells, B cells and stem cells. BC8 is linked to...
by Peter Ciszewski | Dec 6, 2017
Ovid Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to TAK-935/OV935 for the treatment of Dravet syndrome, a severe and rare form of childhood epilepsy that typically presents during the first year of...
by Peter Ciszewski | Nov 28, 2017
Amit Rakhit, MD, Chief Medical and Portfolio Officer of Ovid Therapeutics, discusses the importance of investigating Ovid’s therapies in younger patients suffering from Fragile X and Angelman syndromes. Fragile X syndrome is a genetic condition that causes a...
by Peter Ciszewski | Nov 28, 2017
Amit Rakhit, MD, Chief Medical and Portfolio Officer at Ovid Therapeutics, discusses OV101, a compound that was originally developed to treat insomnia, but is now being studed in Angelman and Fragile X syndromes. OV101 (gaboxadol) is believed to be the only delta...
by Peter Ciszewski | Nov 27, 2017
Sobi received approval from Health Canada for an oral suspension formulation of Orfadin (nitisinone). Orfadin is the first medicine approved in multiple countries globally for use in combination with dietary restriction of tyrosine and phenylalanine in the treatment...
